THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

FDA panel backs diabetes pill linked to heart risk

Dr. Steven Nissen, author of an article on Avandia's risks, makes rounds at the Cleveland Clinic. Dr. Steven Nissen, author of an article on Avandia's risks, makes rounds at the Cleveland Clinic. (Jim Baron/getty images/for the boston globe)
By Diedtra Henderson
Globe Staff / July 31, 2007

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Avandia, once the world's top-selling diabetes pill, should remain on the market, federal advisers said yesterday, but many recommended that the drug carry stronger warnings about its heart risks. (Full article: 927 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass